HUTCHMED (HCM) Competitors $12.08 +0.17 (+1.39%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCM vs. KRYS, IBRX, NUVL, PCVX, and KYMRShould you buy HUTCHMED stock or one of its competitors? MarketBeat compares HUTCHMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HUTCHMED include Krystal Biotech (KRYS), ImmunityBio (IBRX), Nuvalent (NUVL), Vaxcyte (PCVX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. HCM vs. KRYSHCM vs. IBRXHCM vs. NUVLHCM vs. PCVXHCM vs. KYMRHow does HUTCHMED compare to Krystal Biotech?HUTCHMED (NASDAQ:HCM) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Does the media prefer HCM or KRYS? In the previous week, Krystal Biotech had 5 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Krystal Biotech and 6 mentions for HUTCHMED. Krystal Biotech's average media sentiment score of 0.89 beat HUTCHMED's score of -0.13 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, HCM or KRYS? HUTCHMED has higher revenue and earnings than Krystal Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$548.51M3.84$456.91MN/AN/AKrystal Biotech$389.13M23.07$204.83M$7.4840.71 Which has more volatility and risk, HCM or KRYS? HUTCHMED has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Is HCM or KRYS more profitable? Krystal Biotech has a net margin of 53.92% compared to HUTCHMED's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Krystal Biotech 53.92%19.25%17.62% Do analysts prefer HCM or KRYS? HUTCHMED presently has a consensus price target of $16.88, suggesting a potential upside of 39.75%. Krystal Biotech has a consensus price target of $324.11, suggesting a potential upside of 6.43%. Given HUTCHMED's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders hold more shares of HCM or KRYS? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryKrystal Biotech beats HUTCHMED on 11 of the 15 factors compared between the two stocks.How does HUTCHMED compare to ImmunityBio?HUTCHMED (NASDAQ:HCM) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Do analysts recommend HCM or IBRX? HUTCHMED currently has a consensus price target of $16.88, suggesting a potential upside of 39.75%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 84.34%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more volatility & risk, HCM or IBRX? HUTCHMED has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Does the media prefer HCM or IBRX? In the previous week, ImmunityBio had 46 more articles in the media than HUTCHMED. MarketBeat recorded 52 mentions for ImmunityBio and 6 mentions for HUTCHMED. ImmunityBio's average media sentiment score of 0.16 beat HUTCHMED's score of -0.13 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 7 Very Positive mention(s) 6 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals believe in HCM or IBRX? 8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 69.5% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is HCM or IBRX more profitable? HUTCHMED has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A ImmunityBio -606.15%N/A -59.53% Which has better earnings & valuation, HCM or IBRX? HUTCHMED has higher revenue and earnings than ImmunityBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$548.51M3.84$456.91MN/AN/AImmunityBio$140.98M57.23-$351.40M-$0.85N/A SummaryHUTCHMED and ImmunityBio tied by winning 7 of the 14 factors compared between the two stocks.How does HUTCHMED compare to Nuvalent?Nuvalent (NASDAQ:NUVL) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Do insiders and institutionals hold more shares of NUVL or HCM? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor NUVL or HCM? In the previous week, HUTCHMED had 5 more articles in the media than Nuvalent. MarketBeat recorded 6 mentions for HUTCHMED and 1 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.00 beat HUTCHMED's score of -0.13 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, NUVL or HCM? HUTCHMED has higher revenue and earnings than Nuvalent. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$425.38M-$6.06N/AHUTCHMED$548.51M3.84$456.91MN/AN/A Do analysts rate NUVL or HCM? Nuvalent currently has a consensus price target of $137.25, suggesting a potential upside of 34.85%. HUTCHMED has a consensus price target of $16.88, suggesting a potential upside of 39.75%. Given HUTCHMED's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.88HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Is NUVL or HCM more profitable? HUTCHMED's return on equity of 0.00% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -40.11% -35.43% HUTCHMED N/A N/A N/A Which has more risk & volatility, NUVL or HCM? Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. SummaryHUTCHMED beats Nuvalent on 7 of the 13 factors compared between the two stocks.How does HUTCHMED compare to Vaxcyte?Vaxcyte (NASDAQ:PCVX) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Do analysts rate PCVX or HCM? Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 81.88%. HUTCHMED has a consensus target price of $16.88, indicating a potential upside of 39.75%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Is PCVX or HCM more profitable? HUTCHMED's return on equity of 0.00% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -32.51% -29.51% HUTCHMED N/A N/A N/A Which has more risk & volatility, PCVX or HCM? Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Does the media favor PCVX or HCM? In the previous week, HUTCHMED had 2 more articles in the media than Vaxcyte. MarketBeat recorded 6 mentions for HUTCHMED and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.49 beat HUTCHMED's score of -0.13 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in PCVX or HCM? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings and valuation, PCVX or HCM? HUTCHMED has higher revenue and earnings than Vaxcyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$766.63M-$6.88N/AHUTCHMED$548.51M3.84$456.91MN/AN/A SummaryHUTCHMED beats Vaxcyte on 7 of the 13 factors compared between the two stocks.How does HUTCHMED compare to Kymera Therapeutics?HUTCHMED (NASDAQ:HCM) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Does the media refer more to HCM or KYMR? In the previous week, HUTCHMED had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for HUTCHMED and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.42 beat HUTCHMED's score of -0.13 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, HCM or KYMR? HUTCHMED has higher revenue and earnings than Kymera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$548.51M3.84$456.91MN/AN/AKymera Therapeutics$39.21M168.02-$311.35M-$3.57N/A Is HCM or KYMR more profitable? HUTCHMED has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. HUTCHMED's return on equity of 0.00% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Kymera Therapeutics -611.94%-24.71%-22.05% Do institutionals and insiders have more ownership in HCM or KYMR? 8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, HCM or KYMR? HUTCHMED has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Do analysts recommend HCM or KYMR? HUTCHMED presently has a consensus target price of $16.88, suggesting a potential upside of 39.75%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 47.45%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40Kymera Therapeutics 1 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 2.95 SummaryHUTCHMED and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCM vs. The Competition ExportMetricHUTCHMEDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$3.35B$6.33B$12.33BDividend YieldN/A2.32%2.80%5.36%P/E RatioN/A18.8920.8825.51Price / Sales3.84279.14520.5073.06Price / Cash4.47125.3543.1855.00Price / Book1.686.9010.017.03Net Income$456.91M$24.18M$3.54B$334.92M7 Day Performance-4.85%0.77%0.38%-0.40%1 Month Performance-18.80%-0.38%-0.02%1.07%1 Year Performance-8.66%63.37%35.07%34.65% HUTCHMED Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCMHUTCHMED3.5473 of 5 stars$12.08+1.4%$16.88+39.8%-10.2%$2.11B$548.51MN/A1,796News CoverageKRYSKrystal Biotech3.3044 of 5 stars$312.88+2.3%$324.11+3.6%+129.6%$9.01B$389.13M41.83210Analyst ForecastIBRXImmunityBio3.0378 of 5 stars$8.11-4.7%$14.20+75.1%+177.6%$8.91B$140.98MN/A590Trending NewsAnalyst ForecastGap DownNUVLNuvalent2.3373 of 5 stars$104.55-0.7%$137.25+31.3%+34.8%$8.28BN/AN/A40PCVXVaxcyte2.8889 of 5 stars$53.99+1.8%$86.00+59.3%+29.0%$7.65BN/AN/A160 Related Companies and Tools Related Companies KRYS Alternatives IBRX Alternatives NUVL Alternatives PCVX Alternatives KYMR Alternatives QGEN Alternatives TGTX Alternatives MIRM Alternatives SYRE Alternatives RYTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
